BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26951551)

  • 21. The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.
    Verret B; Sourisseau T; Stefanovska B; Mosele F; Tran-Dien A; André F
    Cancer Res; 2020 Aug; 80(15):3062-3069. PubMed ID: 32245795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
    Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
    Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial experience with genomic profiling of heavily pretreated breast cancers.
    Staren ED; Braun D; Tan B; Gupta D; Kim S; Kramer K; Markman M
    Ann Surg Oncol; 2014 Oct; 21(10):3216-22. PubMed ID: 25047475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
    Roukos DH
    Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.
    Hoadley KA; Siegel MB; Kanchi KL; Miller CA; Ding L; Zhao W; He X; Parker JS; Wendl MC; Fulton RS; Demeter RT; Wilson RK; Carey LA; Perou CM; Mardis ER
    PLoS Med; 2016 Dec; 13(12):e1002174. PubMed ID: 27923045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular targeted therapy and genomic evolution of breast cancer].
    Sato F; Toi M
    Nihon Rinsho; 2015 Aug; 73(8):1364-72. PubMed ID: 26281691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer.
    Sunami E; Vu AT; Nguyen SL; Giuliano AE; Hoon DS
    Ann N Y Acad Sci; 2008 Aug; 1137():171-4. PubMed ID: 18837943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations and expression in breast carcinoma in situ.
    Lukas J; Niu N; Press MF
    Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
    Henry NL; Bedard PL; DeMichele A
    Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
    Eirew P; Steif A; Khattra J; Ha G; Yap D; Farahani H; Gelmon K; Chia S; Mar C; Wan A; Laks E; Biele J; Shumansky K; Rosner J; McPherson A; Nielsen C; Roth AJ; Lefebvre C; Bashashati A; de Souza C; Siu C; Aniba R; Brimhall J; Oloumi A; Osako T; Bruna A; Sandoval JL; Algara T; Greenwood W; Leung K; Cheng H; Xue H; Wang Y; Lin D; Mungall AJ; Moore R; Zhao Y; Lorette J; Nguyen L; Huntsman D; Eaves CJ; Hansen C; Marra MA; Caldas C; Shah SP; Aparicio S
    Nature; 2015 Feb; 518(7539):422-6. PubMed ID: 25470049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
    Zhu W; Qin W; Bradley P; Wessel A; Puckett CL; Sauter ER
    Carcinogenesis; 2005 Jan; 26(1):145-52. PubMed ID: 15375011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates.
    Parrella P; Xiao Y; Fliss M; Sanchez-Cespedes M; Mazzarelli P; Rinaldi M; Nicol T; Gabrielson E; Cuomo C; Cohen D; Pandit S; Spencer M; Rabitti C; Fazio VM; Sidransky D
    Cancer Res; 2001 Oct; 61(20):7623-6. PubMed ID: 11606403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The S387Y mutations of the transforming growth factor-beta receptor type I gene is uncommon in metastases of breast cancer and other common types of adenocarcinoma.
    Anbazhagan R; Bornman DM; Johnston JC; Westra WH; Gabrielson E
    Cancer Res; 1999 Jul; 59(14):3363-4. PubMed ID: 10416594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of cell free DNA in breast oncology.
    Canzoniero JV; Park BH
    Biochim Biophys Acta; 2016 Apr; 1865(2):266-74. PubMed ID: 27012505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.
    Dellas A; Torhorst J; Schultheiss E; Mihatsch MJ; Moch H
    Clin Cancer Res; 2002 May; 8(5):1210-6. PubMed ID: 12006540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Damaging Effect of Passenger Mutations on Cancer Progression.
    McFarland CD; Yaglom JA; Wojtkowiak JW; Scott JG; Morse DL; Sherman MY; Mirny LA
    Cancer Res; 2017 Sep; 77(18):4763-4772. PubMed ID: 28536279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.